Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 489 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acne Clear all
Completed Phase 1Phase 2 Interventional

Pharmacokinetic Study of MTC896 Gel in Subjects With Acne

NCT02293018
View directory record Official record
Conditions
Acne Vulgaris
Interventions
0.75% (w/w) MTC896 Gel Once Daily, 0.75% (w/w) MTC896 Gel Twice Daily, 1.5% (w/w) MTC896 Gel Once Daily
Drug
Lead sponsor
Mimetica Pty Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Austin, Texas • College Station, Texas • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris

NCT02801903
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204 4%
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
9 Years to 16 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications

NCT00964366
View directory record Official record
Conditions
Acne Vulgaris
Interventions
clindamycin and benzoyl peroxide, Dapsone gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Phase 2 Interventional

DMT310-001 Topical in the Treatment of Acne Vulgaris

NCT03536637
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DMT310, Hydrogen Peroxide, Placebo
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
San Diego, California • Saint Joseph, Missouri • Henderson, Nevada + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

NCT03028363
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Olumacostat Glasaretil Gel, 5.0%, Olumacostat Glasaretil Gel, Vehicle
Drug · Other
Lead sponsor
Dermira, Inc.
Industry
Eligibility
9 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
38
States / cities
Phoenix, Arizona • Anaheim, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients

NCT04633616
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis, Acne
Interventions
Tailored Patient-Provider Communication, Non-Tailored Patient-Provider Communication
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products

NCT01313728
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone plus Tretinoin Gel, Tretinoin Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Oct 21, 2026, 11:13 PM EDT
Not listed Phase 4 Interventional

Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris

NCT01448733
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
Drug
Lead sponsor
Zeichner, Joshua, M.D.
Individual
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients

NCT01160848
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Area cleaned with saline water and occluded with Tegaderm, Area cleaned with saline water, Area cleaned with Ethyl alcohol solution, Visonac left on the skin for 24 hours in facial area one, Visonac wiped off after one hour, Visonac left on the skin 24 hours in facial area two
Drug
Lead sponsor
Photocure
Industry
Eligibility
12 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Two Different 10.0% Benzoyl Peroxide Creams for Mild to Moderate Acne Vulgaris

NCT00787943
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Topical benzoyl peroxide 10.0% cream - Formulation 1, Topical benzoyl peroxide 10.0% cream - Formulation 2
Drug
Lead sponsor
Northwestern University
Other
Eligibility
13 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne

NCT00975143
View directory record Official record
Conditions
Severe Nodular Acne
Interventions
CIP-Isotretinoin, Isotretinoin
Drug
Lead sponsor
Cipher Pharmaceuticals Inc.
Industry
Eligibility
12 Years to 54 Years
Enrollment
925 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
37
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Fremont, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

NCT02938494
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-123 Lotion, Tazorac Cream, Vehicle Lotion, Vehicle Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Encinitas, California • Fremont, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Not applicable Interventional Results available

The Use of Bellafill for Atrophic Acne Scar Correction in the Full Facial Area

NCT02642627
View directory record Official record
Conditions
Atrophic Acne Scarring
Interventions
Bellafill
Device
Lead sponsor
Suneva Medical, Inc.
Industry
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Not applicable Interventional

Comparison of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminium Garnet (EO QS Nd:YAG) Laser to a Fractionated Laser System

NCT00955461
View directory record Official record
Conditions
Photodamage, Irregular Pigmentation, Acne Scars
Interventions
RevLite laser treatment, Fractionated Laser treatment
Procedure
Lead sponsor
ConBio, a Cynosure Company
Industry
Eligibility
25 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris

NCT02720627
View directory record Official record
Conditions
Acne Vulgaris
Interventions
cortexolone 17α-propionate
Drug
Lead sponsor
Cassiopea SpA
Industry
Eligibility
9 Years to 11 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Fort Smith, Arkansas • San Diego, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 21, 2026, 11:13 PM EDT
Active, not recruiting Phase 2 Interventional

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

NCT06993610
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Tibulizumab Dose A, Tibulizumab Dose B, Placebo
Biological · Other
Lead sponsor
Zura Bio Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 11:13 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Pilot Study Testing Fractional Radiofrequency Versus Fractional Photothermolysis for the Treatment of Acne Scars

NCT01976260
View directory record Official record
Conditions
Cicatrix
Interventions
Fractional Radiofrequency, 1550-nm Fractional Photothermolysis
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Phase 3 Interventional

A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris

NCT00663286
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-110, Clindamycin, Benzoyl peroxide, Vehicle
Drug
Lead sponsor
Dow Pharmaceutical Sciences
Industry
Eligibility
12 Years to 70 Years
Enrollment
1,399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
33
States / cities
Hot Springs, Arkansas • New Haven, Connecticut • Hockessin, Delaware + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris

NCT03599193
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Lotion, 0.1%, Tazarotene Cream, 0.1%
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
9 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 21, 2026, 11:13 PM EDT
Not listed Not applicable Interventional

Using a Cold Atmospheric Plasma Device to Treat Skin Disorders

NCT02759900
View directory record Official record
Conditions
Actinic Keratosis, Acne/Rosacea, Verruca Plana, Tinea, Molluscum Contagiosum, Bowen's Disease, Warts
Interventions
Non-thermal, atmospheric plasma to treat skin lesions and acne, Indirect non-thermal, atmospheric plasma to treat hair loss and acne
Device
Lead sponsor
The Skin Center Dermatology Group
Industry
Eligibility
4 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Phase 2 Interventional

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

NCT04104685
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FCD105, 3% Minocycline Foam, 0.3% Adapalene Foam, Vehicle Foam
Combination Product · Drug · Other
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
12 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
35
States / cities
Bryant, Arkansas • Rogers, Arkansas • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical In-Use Evaluation to Assess the Tolerability and Efficacy of a Moisturizer on Acne Prone Skin

NCT07224633
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Use of Barrier Building Moisturizer
Other
Lead sponsor
Kenvue Brands LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne

NCT00706433
View directory record Official record
Conditions
Acne Vulgaris
Interventions
aminolevulinic acid HCL (ALA), Vehicle (VEH)
Drug · Other
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2011 · Synced Oct 21, 2026, 11:13 PM EDT
Completed Phase 1 Interventional

Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris

NCT02849860
View directory record Official record
Conditions
Acne
Interventions
IDP-121 Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 21, 2026, 11:13 PM EDT